B J Monk

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study
    Lari Wenzel
    Center for Health Policy Research, Division of General Internal Medicine, College of Medicine, University of California, Irvine, USA
    J Clin Oncol 23:5605-12. 2005
  2. ncbi Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study
    Bradley J Monk
    University of California, Irvine Medical Center, Orange, CA 92868, USA
    J Clin Oncol 27:4649-55. 2009
  3. ncbi Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial
    Bradley J Monk
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive, Building 23, Room 107, Orange, CA 92868, USA
    Gynecol Oncol 96:721-8. 2005
  4. ncbi The spectrum and clinical sequelae of human papillomavirus infection
    Bradley J Monk
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive, Orange, CA 92868 3298, USA
    Gynecol Oncol 107:S6-13. 2007
  5. ncbi Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer
    Bradley J Monk
    University of California at Irvine UCI and UCI Medical Center, Orange, CA 92868 3298, USA
    J Clin Oncol 28:3107-14. 2010
  6. ncbi Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer
    Bradley J Monk
    University of California Irvine Medical Center, Orange, CA 92868, USA
    J Clin Oncol 28:3562-9. 2010
  7. ncbi Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials
    Bradley J Monk
    Department of Ob Gyn, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, and Department of Radiation Oncology, Delaware County Memorial Hospital, Drexel Hill, PA 19026, USA
    Gynecol Oncol 105:427-33. 2007
  8. ncbi Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study
    Bradley J Monk
    University of California, Irvine Medical Center, Bldg 56, Room 262, 101 The City Dr, Orange, CA 92868 USA
    J Clin Oncol 27:1069-74. 2009
  9. ncbi Will widespread human papillomavirus prophylactic vaccination change sexual practices of adolescent and young adult women in America?
    Bradley J Monk
    Department of Obstrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine Medical Center, Chao Family Comprehensive Cancer Center, Orange, 92868, USA
    Obstet Gynecol 108:420-4. 2006
  10. ncbi What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States experience and debate
    B J Monk
    Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California Irvine, Medical Center, Orange, California 92868, USA
    Int J Gynecol Cancer 15:199-205. 2005

Research Grants

  1. Strategies Against HPV Related Genital Diseases in Women
    Bradley Monk; Fiscal Year: 2006

Detail Information

Publications95

  1. ncbi Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study
    Lari Wenzel
    Center for Health Policy Research, Division of General Internal Medicine, College of Medicine, University of California, Irvine, USA
    J Clin Oncol 23:5605-12. 2005
    ..Interestingly, there were fewer complaints of neurotoxicity at 6 months among patients who did versus did not undergo interval secondary cytoreduction...
  2. ncbi Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study
    Bradley J Monk
    University of California, Irvine Medical Center, Orange, CA 92868, USA
    J Clin Oncol 27:4649-55. 2009
    ..Assess toxicity and efficacy of cisplatin (Cis) doublet combinations in advanced and recurrent cervical carcinoma...
  3. ncbi Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial
    Bradley J Monk
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive, Building 23, Room 107, Orange, CA 92868, USA
    Gynecol Oncol 96:721-8. 2005
    ....
  4. ncbi The spectrum and clinical sequelae of human papillomavirus infection
    Bradley J Monk
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive, Orange, CA 92868 3298, USA
    Gynecol Oncol 107:S6-13. 2007
    ..Other non-oncogenic HPV types including HPV types 6 and 11 are associated with over 90% of benign HPV-related lesions such as genital warts and juvenile respiratory papillomatosis...
  5. ncbi Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer
    Bradley J Monk
    University of California at Irvine UCI and UCI Medical Center, Orange, CA 92868 3298, USA
    J Clin Oncol 28:3107-14. 2010
    ....
  6. ncbi Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer
    Bradley J Monk
    University of California Irvine Medical Center, Orange, CA 92868, USA
    J Clin Oncol 28:3562-9. 2010
    ..In cervical cancer, EGFR and HER2/neu overexpression and high microvascular density correlate with survival...
  7. ncbi Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials
    Bradley J Monk
    Department of Ob Gyn, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, and Department of Radiation Oncology, Delaware County Memorial Hospital, Drexel Hill, PA 19026, USA
    Gynecol Oncol 105:427-33. 2007
    ..To explore clinical/pathologic factors associated with prognosis of patients with locally advanced cervical carcinoma treated with weekly cisplatin and pelvic radiation...
  8. ncbi Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study
    Bradley J Monk
    University of California, Irvine Medical Center, Bldg 56, Room 262, 101 The City Dr, Orange, CA 92868 USA
    J Clin Oncol 27:1069-74. 2009
    ..The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerability of bevacizumab, a recombinant humanized anti-vascular endothelial growth factor monoclonal antibody...
  9. ncbi Will widespread human papillomavirus prophylactic vaccination change sexual practices of adolescent and young adult women in America?
    Bradley J Monk
    Department of Obstrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine Medical Center, Chao Family Comprehensive Cancer Center, Orange, 92868, USA
    Obstet Gynecol 108:420-4. 2006
    ..The suggestion that widespread vaccination will alter sexual practices is refuted and the rationale for the vaccination of all girls and boys is outlined...
  10. ncbi What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States experience and debate
    B J Monk
    Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California Irvine, Medical Center, Orange, California 92868, USA
    Int J Gynecol Cancer 15:199-205. 2005
    ..The purpose of this study is not to provide an exhaustive review but rather to outline this debate and focus on the American experience with conservative surgery in the management of epithelial ovarian carcinoma...
  11. ncbi Reimbursement for surgical procedures in gynecologic oncology
    B J Monk
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine Medical Center, Chao Family Comprehensive Cancer Center, Orange, California 92868 3298, USA
    Curr Opin Oncol 13:390-3. 2001
    ....
  12. ncbi Anti-angiogenesis agents in metastatic or recurrent cervical cancer
    Bradley J Monk
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange CA 92868, USA
    Gynecol Oncol 116:181-6. 2010
    ..Other intracellular tyrosine kinase inhibitors (TKIs) of angiogenesis such as pazopanib are also encouraging, especially in lieu of their oral administration. Further study of angiogenesis and its inhibition are ongoing...
  13. ncbi Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer
    Bradley J Monk
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 1012 The City Drive, Orange, CA 92868, USA
    Gynecol Oncol 102:140-4. 2006
    ..We reviewed our experience with BEV in patients with recurrent advanced epithelial ovarian cancer who had failed multiple prior chemotherapeutic regimens...
  14. ncbi Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions
    Bradley J Monk
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    J Clin Oncol 25:2952-65. 2007
    ..Quality of life during and after multimodality therapy is considered as well as ongoing clinical trials and future directions...
  15. ncbi Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds
    Bradley J Monk
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California Irvine, 101 The City Drive, Orange, CA 92868, USA
    Int J Gynecol Cancer 19:S63-7. 2009
    ..The objective of this review is to outline the transition away from platinum doublets toward nonplatinum combinations and review emerging data on antiangiogenesis therapy in this setting...
  16. ncbi A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer
    Troy A Gatcliffe
    Department of Ob Gyn, Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 112:85-9. 2009
    ..The objective of this study was to assess the feasibility of adding weekly topotecan to cisplatin in patients with primary, locally advanced carcinoma of the cervix receiving pelvic irradiation...
  17. ncbi Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study
    John K Chan
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, Division of Gynecologic Oncology, San Francisco School of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143 1702, USA
    Gynecol Oncol 116:307-11. 2010
    ..This study aimed to evaluate the clinical outcome of recurrent early-stage high-risk epithelial ovarian cancer patients...
  18. ncbi The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco School of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143 1702, USA
    Gynecol Oncol 116:301-6. 2010
    ..three cycles of chemotherapy. We proposed to identify subsets of patients who may benefit from more cycles of chemotherapy...
  19. ncbi A comparison of intracavitary versus interstitial irradiation in the treatment of cervical cancer
    B J Monk
    Department of Obstetrics and Gynecology, Texas Tech University Health Sciences Center, Southwest Cancer Center, Lubbock 79430, USA
    Gynecol Oncol 67:241-7. 1997
    ....
  20. ncbi Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study
    Rachelle Lanciano
    Department of Radiation Oncology, Delaware County Memorial Hospital, Drexel Hill, PA 19026, USA
    J Clin Oncol 23:8289-95. 2005
    ..This trial was designed to compare the outcome of protracted venous infusion (PVI) fluorouracil (FU) with standard weekly cisplatin and concurrent radiation therapy (RT)...
  21. ncbi Chemotherapy in the management of cervical carcinoma
    Nefertiti C dupont
    University of California, Irvine College of Medicine, 92868, USA
    Clin Adv Hematol Oncol 4:279-86. 2006
    ..Newer innovative agents are needed to treat metastatic and recurrent cervical cancer...
  22. ncbi Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma
    Devansu Tewari
    Chao Family Comprehensive Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine-Medical Center, 101 The City Drive, Orange, CA 92868, USA
    Invest New Drugs 22:475-80. 2004
    ....
  23. ncbi Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma
    Krishnansu S Tewari
    The Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California, Irvine-Medical Center, 101 The City Drive, Orange, CA 92868, USA
    Gynecol Oncol 98:360-8. 2005
    ..It is possible that assay results at diagnosis could be used to guide subsequent therapy at relapse, especially when recurrent tissue is not available for analysis...
  24. ncbi Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
    Ernest S Han
    University of California Irvine, Orange, CA, USA
    Gynecol Oncol 119:484-90. 2010
    ..Potential predictive/prognostic angiogenic markers were prospectively examined in a phase II trial of bevacizumab in epithelial ovarian cancer (EOC)/primary peritoneal cancer (PPC)...
  25. ncbi Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women
    J K Chan
    Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California, Irvine--Medical Center, Orange, California 92868, USA
    Obstet Gynecol 97:707-11. 2001
    ..Thus, it may be considered a reasonable alternative to the abdominal approach in medically compromised women...
  26. ncbi Primary invasive carcinoma of the vagina: treatment with interstitial brachytherapy
    K S Tewari
    The Chao Family National Cancer Institute-Designated Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, California, USA
    Cancer 91:758-70. 2001
    ..CONCLUSIONS: Interstitial irradiation can effect local control in the majority of patients with primary carcinoma of the vagina with acceptable morbidity. Long term cure is demonstrable in patients with Stage I-III disease...
  27. ncbi Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study
    John K Chan
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco School of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94143 1702, USA
    Cancer 112:2202-10. 2008
    ..The purpose was to identify the factors predictive of recurrence and survival in patients with high-risk (stage I, grade 3; stage IC, stage II, or clear cell) epithelial ovarian cancer after adjuvant therapy...
  28. ncbi Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study
    Howard D Homesley
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brody School of Medicine, Greenville, NC, USA
    J Clin Oncol 25:526-31. 2007
    ..To determine if paclitaxel added to ifosfamide as first-line treatment for advanced uterine carcinosarcoma (CS) improves overall survival (OS), progression-free survival (PFS), response, and toxicity...
  29. ncbi An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer
    Peter G Rose
    Division of Gynecologic Oncology, Cleveland Clinic and MetroHealth Medical Center, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 120:38-42. 2011
    ..To evaluate clinical activity of weekly topotecan plus carboplatin in patients with platinum-sensitive recurrent ovarian, fallopian tube, or peritoneal carcinoma...
  30. ncbi Development of an in vitro chemo-radiation response assay for cervical carcinoma
    Bradley J Monk
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine, Orange, California 92868, USA
    Gynecol Oncol 87:193-9. 2002
    ..The assay was feasible for examining fresh tumors and may be an important tool for studying RT or drug resistance. Clinical trials to evaluate this assay are indicated...
  31. ncbi Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer
    N Gillette-Cloven
    University of California Irvine, Orange, USA
    J Am Coll Surg 193:626-32. 2001
    ..Additionally, patients with preoperative bowel obstruction and suboptimal residual disease are more likely to have serious morbidity...
  32. ncbi Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix
    M T McHale
    University of California, Irvine, Medical Center, Chao Family Comprehensive Cancer Center, Orange, California, USA
    Obstet Gynecol 98:726-31. 2001
    ..The fertility sparing management of invasive stage IA1 adenocarcinoma of the uterine cervix may also be entertained among women who desire future fertility and have negative margins of resection...
  33. ncbi Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma
    N Arora
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine Medical Center, Orange, California, USA
    Int J Gynecol Cancer 18:369-72. 2008
    ..We present a case of a complete response in a woman with refractory metastatic fallopian tube carcinoma treated with bevacizumab. This report demonstrates the significance of anti-angiogenesis therapy in the treatment of these tumors...
  34. ncbi Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study
    Robert A Burger
    University of California, Irvine Medical Center, Building 56, Room 264, 101 The City Dr, Orange, CA 92868, USA
    J Clin Oncol 25:5165-71. 2007
    ..We conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab, an anti-VEGF monoclonal antibody...
  35. ncbi Topotecan in the management of cervical cancer
    Leslie M Randall-Whitis
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine, 101 The City Dr South, Bldg 56, Suite 210, Orange, CA 92868, USA
    Expert Opin Pharmacother 8:227-36. 2007
    ..This article reviews the pharmacology of topotecan and its evolution as an active agent in advanced and metastatic cervical cancer that is not amenable to cure with surgery or radiotherapy...
  36. ncbi Bevacizumab in the treatment of ovarian cancer
    Ernest S Han
    University of California Irvine, Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA
    Expert Rev Anticancer Ther 7:1339-45. 2007
    ..Bevacizumab offers a novel therapeutic modality in the treatment of epithelial ovarian cancers...
  37. ncbi Supportive care for women with gynecologic cancers
    Dana M Chase
    University of California, Irvine Medical Center, The Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA
    Expert Rev Anticancer Ther 8:227-41. 2008
    ..As these needs are met, the goal is for quality of life to improve; and with the improvement in quality of life we may expect to see improved survival outcomes...
  38. ncbi Systemic therapy for recurrent endometrial cancer: a review of North American trials
    Thanh H Dellinger
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Building 56, Suite 260, 101 The City Drive South, Orange County, CA 92868 3298, USA
    Expert Rev Anticancer Ther 9:905-16. 2009
    ....
  39. ncbi Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study
    Leslie M Randall
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 119:417-21. 2010
    ..To investigate the feasibility of performing a fresh-tissue, in vitro radiation resistance assay (IVRRA) in a cooperative group setting and to assess the association of IVRRA results with clinical outcomes...
  40. ncbi Cervical cancer therapy: current, future and anti-angiogensis targeted treatment
    Lyndsay J Willmott
    University of California, Irvine, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, Orange, CA, USA
    Expert Rev Anticancer Ther 9:895-903. 2009
    ....
  41. ncbi Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy
    Annie Yessaian
    Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California, Irvine-Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 94:61-6. 2004
    ..According to recently published randomized clinical trials, most patients should receive adjuvant postoperative therapy. The benefits of this multimodality approach require randomized study...
  42. ncbi Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study
    Shu Yuan Liao
    Department of Epidemiology, University of California at Irvine, School of Medicine, Irvine, CA, USA
    Gynecol Oncol 116:452-8. 2010
    ....
  43. ncbi Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study
    Leslie M Randall
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 112:583-9. 2009
    ..To determine whether markers of tumor angiogenesis were associated with progression-free survival (PFS) and overall survival (OS) in women with high-risk, early-stage cervical cancer treated on a phase III trial...
  44. ncbi Bevacizumab toxicities and their management in ovarian cancer
    Leslie M Randall
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Building 56 Room 264, 101 The City Dr, Orange CA 92868, USA
    Gynecol Oncol 117:497-504. 2010
    ..The purpose of this review is to discuss the side effect profile of bevacizumab, to discuss proposed mechanisms of these toxicities, and to provide suggestions for management of adverse events...
  45. ncbi The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma
    Krishnansu Sujata Tewari
    Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA 92868, USA
    Clin Adv Hematol Oncol 8:108-15. 2010
    ..In this article we will provide a rationale for the use of non-platinum-based chemotherapy doublets for this patient population...
  46. ncbi Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study
    Bradley J Monk
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA, USA
    J Clin Oncol 23:4617-25. 2005
    ..CONCLUSION: Despite increased toxicity, CT did not significantly reduce patient QOL when compared with cisplatin alone. Patient-reported QOL measures may be an important prognostic tool in advanced cervix cancer...
  47. ncbi Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group
    Krishnansu S Tewari
    Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, CA 92868, USA
    Semin Oncol 36:170-80. 2009
    ..It becomes imperative that we continue to evaluate novel regimens for this disease...
  48. ncbi Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected]
    Edward L Nelson
    Department of Medicine, University of California, Irvine, California 92697, USA
    Clin Cancer Res 14:2111-8. 2008
    ....
  49. ncbi Intent-to-treat analysis of stage Ib and IIa cervical cancer in the United States: radiotherapy or surgery 1988-1995
    W R Brewster
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Irvine, Orange, California, USA
    Obstet Gynecol 97:248-54. 2001
    ..To estimate the patterns of care and outcome of women with early cervical cancer in the United States based on surgical or radiation intent-to-treat principles...
  50. ncbi Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma
    Devansu Tewari
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA
    Gynecol Oncol 102:421-4. 2006
    ..A durable objective response lasting at least 8 months was documented. CONCLUSION: Trabectedin (ET-743) has activity in uterine leiomyosarcoma and warrants further investigation...
  51. ncbi Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study
    Koen De Geest
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Suite 4630 JCP, Iowa City, IA 52242, USA
    J Clin Oncol 28:149-53. 2010
    ....
  52. ncbi HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3
    J K Chan
    Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Br J Cancer 89:1062-6. 2003
    ..In conclusion, HPV status and number of lifetime sexual partners were strongly predictive of regression of untreated CIN 2 and 3...
  53. ncbi Wnt signaling in ovarian tumorigenesis
    T A Gatcliffe
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California USA
    Int J Gynecol Cancer 18:954-62. 2008
    ..The exact mechanisms by which this occurs need to be further elucidated. Wnt signaling is probably involved via multiple, diverse mechanisms. Further research in this area is warranted...
  54. ncbi Recent advances in human papillomavirus vaccines
    Ali Mahdavi
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868-3298, USA
    Curr Oncol Rep 8:465-72. 2006
    ..Cell-based therapeutic vaccines are also being tested. HPV vaccines have the potential to eradicate a major cancer and source of morbidity around the world...
  55. ncbi Vaccines against human papillomavirus and cervical cancer: promises and challenges
    Ali Mahdavi
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine, 101 The City Drive, Building 56, Room 262, Orange, California 92868-3298, USA
    Oncologist 10:528-38. 2005
    ..A number of approaches have shown significant therapeutic benefit in preclinical papillomavirus models and await testing in patient populations to determine the most effective curative strategy...
  56. ncbi Conservative clitoral preservation surgery in the treatment of vulvar squamous cell carcinoma
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305-5317, USA
    Gynecol Oncol 95:152-6. 2004
    ..CONCLUSION: Clitoral-sparing vulvar cancer surgery does not compromise the rate of loco-regional control in patients and may be offered to selected women...
  57. ncbi Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis
    John K Chan
    Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California-Irvine Medical Center, Orange, California 92868, USA
    Cancer 97:568-74. 2003
    ..The role of primary or postoperative radiation with or without chemotherapy is unclear and yields uniformly poor results, particularly in patients with advanced lesions. Clinical trials are needed...
  58. ncbi Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study
    Robert A Burger
    Department of Obstetrics and Gynecology, University of California-Irvine Medical Center, Orange, CA, USA
    Cancer 101:106-15. 2004
    ....
  59. ncbi Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience
    Ali Mahdavi
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, 101 The City Drive, Orange, CA 92868 3298, USA
    Int J Gynecol Cancer 19:1080-4. 2009
    ..Uterine leiomyosarcoma (LMS) is associated with high rate of recurrence after surgical resection. The role of adjuvant radiation therapy in improving survival in women with uterine LMS is unclear...
  60. ncbi Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer
    Bradley J Monk
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Medical Center, 101 The City Drive, Building 56, Room 262, Orange CA 92868, USA
    Gynecol Oncol 96:902-5. 2005
    ..An objective durable response lasting at least 5 months was documented. CONCLUSION: Bevacizumab has activity in epithelial ovarian carcinoma and larger scale trials are indicated...
  61. ncbi Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success?
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143 1702, USA
    J Clin Oncol 26:1511-8. 2008
    ....
  62. ncbi Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion
    Samuel S Im
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California-Irvine Medical Center, 101 The City Drive, Orange, CA 92868, USA
    Clin Cancer Res 9:4145-50. 2003
    ..Despite an increased use of adjuvant radiation therapy, these cancers are still more likely to relapse...
  63. ncbi Is atypical squamous cells that cannot exclude high-grade squamous intraepithelial lesion clinically significant?
    Michael T McHale
    1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Naval Medical Center San Diego, San Diego, CA 92134, USA
    J Low Genit Tract Dis 11:86-9. 2007
    ..To determine the cumulative risk of cervical intraepithelial neoplasia (CIN) 2 or 3 in patients with atypical squamous cells, cannot exclude HSIL (ASC-H)...
  64. ncbi Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer
    Krishnansu S Tewari
    Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive, Building 56, Room 262, Orange, CA 92868-3298, USA
    Curr Oncol Rep 7:419-34. 2005
    ..The need for novel combinations and the implementation of active biologic agents is implicit. The accumulated data in this disease setting, as evidenced by the experience of the GOG, are presented in this review...
  65. ncbi Cervical neoplasia in pregnancy. Part 2: current treatment of invasive disease
    Mark I Hunter
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine, Irvine, CA, USA
    Am J Obstet Gynecol 199:10-8. 2008
    ....
  66. ncbi Assessment and significance of quality of life in women with gynecologic cancer
    Dana M Chase
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Building 56 Room 262, Orange, CA 92868, USA
    Future Oncol 6:1279-87. 2010
    ....
  67. ncbi Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation
    Bradley J Monk
    Division of Gynecologic Oncology, The Chao Family N.C.I.-Designated Comprehensive Cancer Center, University of California, Irvine-Medical Center, Orange, CA 92868, USA
    Int J Radiat Oncol Biol Phys 52:806-15. 2002
    ..In radiotherapy-naive patients with unresectable isolated recurrent gynecologic malignancies, 125I implants and EBRT are feasible and occasionally may contribute to long-term disease-free survival...
  68. ncbi Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease
    Mark I Hunter
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine, Irvine, CA 92868, USA
    Am J Obstet Gynecol 199:3-9. 2008
    ..In the present review, current guidelines regarding cervical cancer screening are reviewed, and data from studies of pregnant populations are summarized...
  69. ncbi Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program
    Neal M Lonky
    Department of Obstetrics and Gynecology, Kaiser Permanente Medical Center, Anaheim, CA, USA
    J Low Genit Tract Dis 11:258-64. 2007
    ....
  70. ncbi Primary invasive vaginal cancer in the setting of the Mayer-Rokitansky-Kuster-Hauser syndrome
    Devansu S Tewari
    Division of Gynecologic Oncology, Division of Radiation Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 101 The City Drive, Orange, CA 92868, USA
    Gynecol Oncol 85:384-7. 2002
    ..It is a reminder that routine gynecologic examinations are still warranted as these patients are at risk for malignant changes in residual mullerian tissues...
  71. ncbi A clinical pathway for postoperative management and early patient discharge: does it work in gynecologic oncology?
    Dana M Chase
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA, USA
    Am J Obstet Gynecol 199:541.e1-7. 2008
    ..This study evaluates a postoperative clinical pathway among gynecologic oncology patients...
  72. ncbi Human papillomavirus vaccine: a new chance to prevent cervical cancer
    Bradley J Monk
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange 92868 3298, USA
    Recent Results Cancer Res 174:81-90. 2007
    ....
  73. ncbi Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group
    Franco M Muggia
    Department of Medicine, Kaplan Cancer Center, Division of Medical Oncology, New York University Medical Center, 462 First Avenue, New York, NY 10016, USA
    Gynecol Oncol 94:483-7. 2004
    ..To evaluate the combination of cisplatin and irinotecan as first-line treatment of patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix...
  74. ncbi Pretreatment CA-125 and risk of relapse in advanced ovarian cancer
    Maurie Markman
    M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 24:1454-8. 2006
    ....
  75. ncbi Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study
    Harry J Long
    Mayo Clinic, Department of Medical Oncology, East 12B Mayo Building, 200 First Street, Southwest, Rochester, MN 55905 0001, USA
    Gynecol Oncol 100:537-43. 2006
    ..The primary endpoint was overall survival (OS), with response rate, progression-free survival (PFS), and quality of life (QOL) as secondary objectives...
  76. ncbi The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination
    Bradley J Monk
    Am J Obstet Gynecol 197:337-9. 2007
  77. ncbi Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study
    Steven E Waggoner
    Department of Reproductive Medicine, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Gynecol Oncol 103:853-8. 2006
    ..To determine if smoking, a known risk factor for a number of cancers including cervical cancer, is associated with poor prognosis in patients with locally advanced cervical carcinoma treated with chemoradiation...
  78. ncbi Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study
    Mitchell Morris
    Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 22:3340-4. 2004
    ..Additional study of this regimen in a phase III setting is justified in this patient population...
  79. ncbi Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study
    Franco M Muggia
    Department of Medicine, Kaplan Cancer Center, New York University Medical Center, 550 First Avenue, New York, NY 10016, USA
    Gynecol Oncol 96:108-11. 2005
    ..A Phase II study with intravenous vinorelbine was initiated for this purpose in patients with Stage IVB, recurrent, or persistent nonsquamous carcinomas who had received one prior chemotherapy or were not eligible for other studies...
  80. ncbi What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
    Ernest S Han
    Gynecol Oncol 105:3-6. 2007
  81. ncbi Photodynamic therapy of high-grade cervical intraepithelial neoplasia with 5-aminolevulinic acid
    Kristin A Keefe
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology at the Chao Family Compressive Cancer Center, Orange, California, USA
    Lasers Surg Med 31:289-93. 2002
    ..CONCLUSIONS: PDT at this light and ALA dose is well tolerated but has minimal activity in the treatment of CIN 2 and CIN 3. Other doses and schedules of light and ALA or novel photosensitizers may improve efficacy...
  82. ncbi An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy
    Ping Yu Liu
    Southwest Oncology Group Statistical Center, Seattle, WA, USA
    J Clin Oncol 25:3615-20. 2007
    ..PATIENTS AND METHODS The EPD criterion was tested on Southwest Oncology Group trial 9701/Gynecologic Oncology Group trial 178 patients (n = 288) and compared with Gynecologic Cancer Intergroup criterion...
  83. ncbi Does the ALTS trial apply to the community-based practitioner?
    Bradley J Monk
    Am J Obstet Gynecol 188:1381-2. 2003
  84. ncbi Reducing the burden of glandular carcinomas of the uterine cervix
    Thomas J Herzog
    Columbia University, Irving Comprehensive Cancer Center, New York Presbyterian Hospital, New York, NY, USA
    Am J Obstet Gynecol 197:566-71. 2007
    ....
  85. ncbi New developments in the treatment of invasive cervical cancer
    Samuel S Im
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine Medical Center; Chao Family Comprehensive Cancer Center, 101 The City Drive, Building 23, Room 107, Orange, CA 92868, USA
    Obstet Gynecol Clin North Am 29:659-72. 2002
    ..Novel treatments for cervical cancer appear to be imminent in the near future...
  86. ncbi Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility study
    Devansu Tewari
    Division of Gynecologic Oncology, University of California Irvine Medical Center, 101 The City Drive South, Orange, CA 92868, USA
    Gynecol Oncol 99:84-91. 2005
    ..The potential of these technologies for cancers in which radiotherapy is employed warrants further investigation...
  87. ncbi Initial lessons learned in HPV vaccination
    Thomas J Herzog
    Columbia University, College of Physicians and Surgeons, Department of Obstetrics and Gynecology, 161 Fort Washington Avenue, 8th Floor New York, NY 10032, USA
    Gynecol Oncol 109:S4-11. 2008
    ..This article also examines the impact of the HPV vaccination awareness campaign on media and public policy dynamics...
  88. ncbi The impact of cervical cancer on quality of life: a personal account
    Christine Baze
    Gynecol Oncol 109:S12-4. 2008
  89. ncbi Role of pegylated liposomal doxorubicin in ovarian cancer
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
    Gynecol Oncol 96:10-8. 2005
    ..The plethora of agents currently available present difficult choices for physicians. The present effort seeks to examine the role of one of these agents, pegylated liposomal doxorubicin...
  90. ncbi Cervical cancer screening
    Dorothy J Wiley
    Division of Primary Care, School of Nursing, University of California at Los Angeles, Los Angeles, CA 90095 6919, USA
    Curr Oncol Rep 6:497-506. 2004
    ..These patients would include organ transplant recipients, women exposed to diethylstilbestrol (DES), and HIV-infected women...
  91. ncbi The new era of cervical cancer prevention: HPV vaccination
    Bradley J Monk
    Gynecol Oncol 109:S1-3. 2008
  92. ncbi Age considerations when vaccinating against HPV
    Thomas C Wright
    Columbia University, New York, New York 10032, USA
    Gynecol Oncol 109:S40-7. 2008
    ..This review discusses the various considerations that should be addressed when making recommendations of who should be vaccinated against HPV...
  93. ncbi Laparoscopic photodynamic diagnosis of ovarian cancer using 5-aminolevulinic acid in a rat model
    John K Chan
    Beckman Laser Institute, University of California-Irvine, Irvine, CA 92612, USA
    Gynecol Oncol 87:64-70. 2002
    ..Human trials are indicated...
  94. ncbi Human papillomavirus infections: truth or consequences
    Bradley J Monk
    Cancer 100:225-7. 2004
  95. ncbi A stiff bristled, spiral-shaped ectocervical brush: a device for transepithelial tissue biopsy
    Bradley J Monk
    Department of Gynecologic Oncology, University of California at Irvine, Irvine, USA
    Obstet Gynecol 100:1276-84. 2002
    ..User training and guidelines for sampling are needed to assure that an adequate sample is collected...

Research Grants1

  1. Strategies Against HPV Related Genital Diseases in Women
    Bradley Monk; Fiscal Year: 2006
    ..It is expected that Dr. Monk will have obtained extramural funding for both his laboratory and clinical studies by the end of the period of support requested. ..